| for the three months ended
June 30, |
for the six months ended
June 30, |
|||||||
| In 000€ | 2021 |
|
2020 (*) |
|
2021 |
|
2020 (*) |
|
| Net profit (loss) for the period | 3,443 |
(1,969) |
(224) |
(4,870) |
||||
| Income taxes | 131 |
(191) |
(25) |
267 |
||||
| Financial cost | 814 |
640 |
5,515 |
2,461 |
||||
| Financial income | (1,968) |
(345) |
(2,556) |
(845) |
||||
| Share in loss of joint venture | - |
39 |
||||||
| Operating (loss) profit | 2,420 |
(1,865) |
2,710 |
(2,948) |
||||
| Depreciation and amortization | 4,845 |
5,015 |
9,926 |
9,777 |
||||
| Corporate research and development | 774 |
687 |
1,466 |
1,478 |
||||
| Corporate headquarter costs | 2,316 |
2,781 |
4,964 |
5,173 |
||||
| Other operating income (expense) | (857) |
(1,074) |
(1,742) |
(1,716) |
||||
| Segment EBITDA | 9,498 |
5,546 |
17,324 |
11,765 |
||||
| (*) The year 2020 has been restated to reflect the final accounting of the business combination with Engimplan. Impact on the year to date operating result of the (83) kEUR |
